Screener
Artivion AORT Foreign — Perclot revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Artivion in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Artivion’s 10-K, filed February 18, 2026.
- Filed
- Feb 18, 2026, 4:14 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-009046
FAQ
- What is Artivion's foreign — perclot revenues?
- Artivion (AORT) reported foreign — perclot revenues of $56.81M in Q4 2025.
- How has Artivion's foreign — perclot revenues changed year-over-year?
- Artivion's foreign — perclot revenues increased by 14.5% year-over-year, from $49.64M to $56.81M.
- What is the long-term trend for Artivion's foreign — perclot revenues?
- Over 4 years (2021 to 2025), Artivion's foreign — perclot revenues has grown at a 11.4% compound annual growth rate (CAGR), from $147.69M to $227.26M.
- What does foreign — perclot revenues mean?
- This metric represents the total revenue generated from the sale of Perclot hemostatic products within international markets outside of the company's domestic region. It serves as a key indicator of the product's adoption rate and market penetration in global surgical settings. Tracking this revenue stream helps investors assess the company's ability to scale specialized medical device sales across diverse regulatory and healthcare environments.
Ask your AI about Artivion's foreign — perclot revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude